In the United States, the mortality rate from colorectal cancer was 12.9 per 100,000 inhabitants in 2019-2023, according to the American Cancer Society. This decline is real, measurable, and profoundly unequal. For Black Americans, this rate is approximately 29% higher than for whites (16.6 versus 12.9 per 100,000 in 2019-2023); in Ontario, Cancer Care Ontario documents survival inequalities between Indigenous populations and the general population.

The Essentials

  • Mortality from colorectal cancer has declined in the United States according to the American Cancer Society, with a rate of 12.9 per 100,000 in 2019-2023.
  • This gap between Black and white Americans is approximately 29% in terms of mortality (16.6 versus 12.9 per 100,000 for 2019-2023): it reflects a set of factors in which inequalities of access to screening and care are major, though available sources do not allow for universal ranking of biological factors.
  • In Ontario, Cancer Care Ontario documents survival inequalities between Indigenous populations and the general population.
  • The central mechanism: diagnostic and therapeutic innovations generally reach patients integrated into established screening pathways first, namely those whose health system is already organized around them.
  • Precision medicine could widen existing gaps if access remains structured by geography and race.

The Decline in Mortality Masks Two Overlapping Epidemics

The overall figure is encouraging. The United States has recorded a decline in colorectal cancer mortality, particularly among those aged 65 and older, linked to declining incidence, expanded screening, and improved treatments. Mortality has increased, however, since 2004 among those under 50 and since 2019 among those aged 50-64. The American Cancer Society today counts approximately 1.5 million colorectal cancer survivors in the United States, a figure in steady growth over the past fifteen years.

But this aggregate figure obscures two diverging trajectories. For a 50-year-old white man with access to stable health insurance, colorectal cancer is today, if detected early, a treatable disease with a five-year survival rate exceeding 90% at the localized stage. Black men living in disadvantaged areas or systems may encounter more barriers to screening, diagnosis, and care.

The mortality approximately 29% higher for Black Americans than for whites (16.6 versus 12.9 per 100,000 for 2019-2023) illustrates this bifurcation. This differential has existed for decades. It has not disappeared with therapeutic progress. In some places, it has narrowed slightly; in other geographic and socioeconomic configurations, it persists unchanged. Data from the American Cancer Society for 2026 confirms that the mortality gap remains one of the largest among all common cancers, making it a particularly legible marker of structural health inequalities.

Screening Determines Outcomes

Colorectal cancer has a valuable particularity from an epidemiological perspective: it develops slowly, often over ten to fifteen years from benign polyps. This long timeframe offers an exceptional window for intervention. Removal of a precancerous polyp reduces the risk of its evolving into cancer, without guaranteeing that no colorectal cancer will develop later. This is why screening is, in this disease more than elsewhere, a major determinant of population outcomes, though not the sole factor in individual survival, which also depends on stage, tumor characteristics, comorbidities, and quality of treatment.

Yet colonoscopy remains a procedure that requires time, a primary care physician, demanding bowel preparation, and in most American systems, insurance covering the procedure and anesthesia. For millions of uninsured Americans, those without a primary care doctor, or those living hours away from a gastroenterology center, these obstacles are prohibitive. The fact that states that expanded Medicaid under the Affordable Care Act display higher colorectal screening rates among low-income populations directly illustrates this mechanism.

Alternatives exist and are progressing. Immunochemical fecal tests, known as FIT, are less invasive, less costly, and can be performed at home. In 2024, the FDA approved Shield, developed by Guardant Health, Inc., a blood test for colorectal cancer screening. It was not the first blood test for colorectal cancer screening approved by the FDA. This test, marketed as Shield, detects circulating tumor DNA signals with approximately 83% sensitivity for cancers and 13% for advanced polyps, according to data from the ECLIPSE study published in the New England Journal of Medicine.

It could overcome several practical barriers to screening.

Regulatory approval and reimbursement are two different things. In 2025, Medicare agreed to cover the Shield test at a rate that sparked debate: some industry stakeholders believed the reimbursement insufficient to ensure broad deployment. Private insurers apply variable policies. For uninsured populations, access to the test remains limited. A diagnostic innovation reserved for patients already integrated into the system improves their care without expanding overall coverage.

The Canadian Case, or the Illusion of Universal Systems

Ontario offers an instructive counterpoint. Canada has a universal healthcare system: in theory, access to cancer care should not depend on income or ethnic origin. Data from the Canadian Partnership Against Cancer tells another story.

Survival inequalities for colorectal cancer have been documented among First Nations in Ontario compared to the general population. In Ontario, despite universal coverage, systemic, social, historical, and geographic barriers persist for First Nations.

General progress shows average survival improving in Ontario, but Indigenous populations, less present in screening pathways for documented historical and geographic reasons, access therapeutic advances on a delayed timeline. This temporal gap between populations contributes to widening observed survival differences.

This phenomenon is well-identified in the public health literature: it is called adoption inequalities for innovations. Medical innovations tend to diffuse first among patients with better access to services. Active policies can accelerate diffusion to underserved populations. Without deliberate intervention, this process can extend over several decades. In Ontario, current data show no sign of spontaneous convergence between Indigenous and general populations.

The Actors Making Progress

Facing these findings, several initiatives chose to work directly on determinants of access rather than only therapeutic aspects.

The National Colorectal Cancer Roundtable, a coalition founded by the American Cancer Society and the Centers for Disease Control and Prevention, has coordinated programs since 2014 aimed at bringing the screening rate to 80% of the eligible population in the United States. The goal has not been met nationally, but some states and integrated healthcare systems have crossed this threshold, notably Kaiser Permanente in California, which exceeded 80% through automatic reminders, FIT tests sent by mail, and coordination teams dedicated to patients at risk of dropping out.

Patient navigation programs, where a coordinator individually accompanies individuals from screening through treatment, have shown measurable results in contexts of high precarity. A study published in Cancer showed that navigation significantly reduced diagnostic resolution delays among Black participants after abnormal screening; the specific effect among Hispanics was not similarly established. The model is resource-intensive in human terms, but its cost-effectiveness is favorable when evaluated across the entire care trajectory.

In Canada, the Prevention and Control of Cancer for First Nations, Inuit, and Métis program, coordinated by the Canadian Partnership Against Cancer, funds culturally adapted approaches, including training navigators from the communities themselves. These community navigators bridge health services and populations that historically lacked trust in them. Preliminary results are encouraging in terms of participation in screening programs, but follow-up on long-term survival indicators remains to be documented.

The question of differentiated access to care is posed in similar terms for other public health domains: removing a financial or regulatory barrier is insufficient if social and cultural barriers remain intact. Colorectal cancer confirms this diagnosis with particular precision, because the therapeutic window is long and delays in screening increase the risk of late-stage diagnosis.

Precision Medicine Tested by Access Inequalities

The years 2025-2035 will likely see a profound transformation in colorectal cancer management. Precision medicine, which adapts treatment to the molecular profile of the tumor, is advancing rapidly for this cancer type. Therapies targeting KRAS, BRAF mutations and microsatellite instabilities have already modified first and second-line protocols. Immune checkpoint inhibitors (immunotherapies) have shown remarkable results for so-called MSI-H tumors, which represent approximately 5% of metastatic colorectal cancers. Ongoing trials explore their use as adjuvant therapy for less advanced stages.

The Shield blood test, and its probable successors, could eventually enable broader population screening without the logistical constraints of colonoscopy. Multi-cancer tests through circulating DNA analysis, of which Grail’s Galleri is a forerunner, are being evaluated in several large-scale studies, including the NHS Galleri Trial in the United Kingdom with 140,000 participants. If these tools confirm their efficacy and become economically accessible, they could transform early detection.

Each of these advances raises the same difficulty: who will have access first, and at what pace will diffusion reach the least well-served populations. The history of colonoscopy illustrates this problem. The technique has existed since the 1970s; screening gaps are particularly marked by income, insurance, education level, and for certain ethnic groups; the Black-white gap measured in available data is small. A technology can leave structural access inequalities intact and make visible the gap between patients who benefited from it and those who waited.

If precision therapies and next-generation blood tests follow the historical trajectory of adoption, access inequalities could persist even as average survival continues to advance. Policies could counter this scenario: expanded coverage of these tests under Medicaid and Canadian public systems, large-scale funding of community navigators, and adaptation of screening protocols to geographic constraints of rural and remote areas. These policies require specific funding, whose viability depends on budgetary priorities. The debate over investment in preventive health systems crosses several developed economies and refers to fundamental political choices about the value placed on reducing health inequalities.

An alternative scenario exists: if community navigation programs expand, if non-invasive tests become reimbursed and easily accessible, and if Indigenous communities and disadvantaged neighborhoods are actively targeted, observed gaps could progressively narrow. Kaiser Permanente data in California show this is technically feasible in an integrated system. The question is whether more fragmented systems, like those in the United States outside major integrated organizations, can reproduce these results at scale.

Organization of Care as a Determinant Variable

What colorectal cancer teaches, with unusual clarity, concerns the organization of care as much as biology. Access to prevention and care depends largely on the structure of the healthcare system in which the patient finds themselves, including its geographic, economic, and institutional variables.

States that expanded Medicaid saw measurable improvements in screening access for their low-income populations. Integrated systems with shared electronic medical records and automatic reminders achieve higher screening rates than fragmented systems. Communities with care navigators trained in their cultural realities participate more in prevention programs. These results are documented and reproducible. They show that observed gaps are closely linked to healthcare system organization choices.

The challenge for the coming years is simple to state, difficult to execute: ensuring that the next diagnostic and therapeutic innovations reach all populations simultaneously, rather than sequentially according to usual gradients of access. This requires anticipated coverage decisions, investments in local infrastructure, and systematic evaluation of adoption inequalities at each stage of deploying a new tool. Without deliberate interventions, technological and therapeutic progress risks diffusing according to historical patterns, which could consolidate existing access inequalities.

Sources

  1. American Cancer Society, Cancer Statistics 2026
  2. Canadian Partnership Against Cancer, reports on survival inequalities in Ontario, 2015-2023, partnershipagainstcancer.ca
  3. National Institutes of Health, epidemiological data on colorectal cancer, nih.gov
  4. ECLIPSE Study, New England Journal of Medicine, 2024, results of Shield blood test (Guardant Health) for colorectal cancer detection
  5. National Colorectal Cancer Roundtable, 80% by 2018 program and follow-up, American Cancer Society / CDC